The BARD1 (ASX:BD1) share price eyes record highs after positive research results

The BARD1 Life Sciences (ASX: BD1) share price is on watch today after positive results from the evaluation of its EXO-NET product in pancreatic cancer. 

Let’s take a closer look at the announcement and what this means for the BARD1 share price. 

What’s driving the BARD1 share price higher? 

BARD1 maintains a cancer diagnostics portfolio. This includes the commercialised hTRET test which is used as a supplement to urine cytology tests. Additionally, the portfolio also includes diagnostics tests in development for ovarian, breast, lung, prostate, and pancreatic cancers. The group is working towards commercialising its…